[ALDR] Alder BioPharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 22.5 Change: 1.45 (6.89%)
Ext. hours: Change: 0 (0%)

chart ALDR

Refresh chart

Strongest Trends Summary For ALDR

ALDR is in the long-term down -80% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alder Biopharmaceuticals Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia. It is developing monoclonal antibodies comprising ALD403, which has completed Phase Ib proof-of-concept trials to target calcitonin gene-related peptide for the prevention of migraine; and Clazakizumab that has completed Phase IIb clinical trials that inhibits the pro-inflammatory cytokine interleukin-6 in the treatment of rheumatoid arthritis and psoriatic arthritis. The company also has preclinical programs in the discovery phase for various indications. Alder Biopharmaceuticals Inc. has a collaboration with Bristol-Myers Squibb Company for the development of Clazakizumab. Alder Biopharmaceuticals Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-4.47 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.91
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-0.14% ROE-0.15% ROI
Current Ratio36.49 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities190.83 M Cash From Investing Activities-11.65 M Cash From Operating Activities-16.05 M Gross Profit
Net Profit-14.65 M Operating Profit-14.71 M Total Assets242.94 M Total Current Assets241.6 M
Total Current Liabilities6.62 M Total Debt Total Liabilities6.78 M Total Revenue
Technical Data
High 52 week18.6 Low 52 week9.8 Last close11.65 Last change1.48%
RSI60.85 Average true range0.75 Beta1.6 Volume534.94 K
Simple moving average 20 days9.03% Simple moving average 50 days-3.31% Simple moving average 200 days-14.66%
Performance Data
Performance Week13.11% Performance Month4.86% Performance Quart-13.45% Performance Half-3.72%
Performance Year4.48% Performance Year-to-date13.66% Volatility daily4.21% Volatility weekly9.41%
Volatility monthly19.28% Volatility yearly66.78% Relative Volume264.97% Average Volume887.27 K
New High New Low

News

2019-06-11 08:02:54 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-06-10 08:05:19 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-06-04 14:18:53 | Imagine Owning Alder BioPharmaceuticals NASDAQ:ALDR While The Price Tanked 65%

2019-06-04 08:05:11 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-05-24 16:05:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-05-14 16:05:00 | Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences

2019-05-08 08:00:00 | Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention

2019-05-07 11:21:35 | Here’s What Hedge Funds Think About Alder Biopharmaceuticals Inc ALDR

2019-05-07 08:04:43 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-05-06 09:58:01 | Geron's GERN Q1 Earnings Beat, Revenues Miss, Stock Up

2019-05-06 08:00:00 | Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials

2019-05-03 13:00:00 | Bob Azelby awaits approval of Alder’s migraine drug

2019-05-03 07:27:15 | Edited Transcript of ALDR earnings conference call or presentation 2-May-19 9:00pm GMT

2019-05-02 23:58:44 | Alder BioPharmaceuticals, Inc. ALDR Q1 2019 Earnings Call Transcript

2019-05-02 18:27:24 | Alder BioPharmaceuticals: 1Q Earnings Snapshot

2019-04-30 08:04:50 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-04-26 16:05:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-04-26 16:05:00 | Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results

2019-04-26 06:10:23 | Analysts point to potential Biogen M&A options after Alzheimer's failure

2019-04-23 16:38:39 | Why This Migraine-Focused Biotech Stock Could Be The Next Takeover

2019-04-23 08:08:52 | The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale

2019-04-23 08:00:00 | Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting

2019-04-22 16:34:57 | U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab

2019-04-19 16:19:56 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-04-12 16:05:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-04-08 16:05:00 | Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer

2019-04-05 19:10:05 | Alder Biopharmaceuticals CEO: Spreading migraine awareness

2019-04-02 08:00:00 | Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference

2019-03-12 10:28:30 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-03-06 08:02:57 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-03-05 08:03:14 | See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

2019-03-05 08:00:00 | Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference

2019-03-04 18:48:39 | Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares

2019-03-01 08:30:00 | Recent Analysis Shows McDermott International, Nu Skin Enterprises, Marcus, Keysight Technologies, Alder BioPharmaceuticals, and LendingTree Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-27 20:07:36 | Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock

2019-02-26 20:40:39 | Edited Transcript of ALDR earnings conference call or presentation 25-Feb-19 10:00pm GMT

2019-02-26 16:01:00 | Alder BioPharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

2019-02-25 22:06:01 | Alder BioPharmaceuticals Inc ALDR Q4 2018 Earnings Conference Call Transcript

2019-02-25 16:05:00 | Alder BioPharmaceuticals® Reports Fourth Quarter and Full Year 2018 Financial and Operating Results

2019-02-25 15:00:00 | Alder Biopharmaceuticals, Inc. to Host Earnings Call

2019-02-22 16:16:52 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2019-02-22 08:00:00 | Alder BioPharmaceuticals® Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab

2019-02-21 17:17:19 | Alder BioPharmaceuticals® to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-19 16:05:00 | Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial and Operating Results

2019-02-14 15:30:43 | Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst

2019-02-14 07:20:00 | Consolidated Research: 2019 Summary Expectations for Varonis, Dolby Laboratories, Alder BioPharmaceuticals, Retail Properties of America, Cerus, and Motorcar Parts of America — Fundamental Analysis, Key Performance Indications

2019-02-12 08:52:01 | Molina Healthcare MOH Q4 Earnings & Revenues Top Estimates

2019-02-08 10:05:03 | Ensign Group's ENSG Q4 Earnings Top Estimates, Surge Y/Y

2019-02-08 10:03:03 | MEDNAX MD Q4 Earnings Surpass Estimates, Increase Y/Y

2019-02-07 10:34:03 | Is a Beat in Store for Molina Healthcare MOH Q4 Earnings?